Oncology

Stipe Therapeutics (STipe) has raised USD 22 Million to move forward its clinical development of novel candidates to target intracellular protein-protein interactions of the STING Pathway. The financing round was led by Sunstone Life Science Ventures Fund IV, Novo Holdings, Arix Bioscience, and Wellington Partners Life Science V Fund. STipe, an immuno-oncology company, with its STING pathway is planning to target a wide range of haematological and solid tumors. The company promises of the increased sensitivity of the immune system while detecting tumorous cells by its STING pathway. The pathway changes the environment tumour prospers in and accelerates the anti...